CFO
ALXN

CVA Family Office’s Alexion Pharmaceuticals ALXN Stock Holding History

CVA Family Office’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed -$11K – 931
2021
Q3 		$11K Sell
100
-145
-59% -$26.6K 0.01% 293
2021
Q2 		$45K Buy
245
+5
+2% +$858 0.01% 382
2021
Q1 		$37K Buy
240
+140
+140% +$21.7K 0.01% 311
2020
Q4 		$16K Hold
100
– – 0.01% 280
2020
Q3 		$11K Hold
100
– – 0.01% 293
2020
Q2 		$11K Hold
100
– – 0.01% 257
2020
Q1 		$9K Buy
+100
New +$9.81K 0.01% 246

Other funds holding ALXN

RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office's ALXN Position: Q4 2021 in Review

CVA Family Office sold out of Alexion Pharmaceuticals (ALXN) in Q4 2021, closing a stake of 100 shares — an estimated $11K sold.

CVA Family Office first reported a position in ALXN in Q1 2020 and held it in 7 quarters. The position peaked at $45K in Q2 2021. 2 funds tracked by Wall St. Rank hold ALXN as of Q4 2021.

  • CVA Family Office reported no remaining Alexion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • CVA Family Office sold 100 Alexion Pharmaceuticals shares in Q4 2021, an estimated $11K.
  • CVA Family Office first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 7 quarters.
  • CVA Family Office's Alexion Pharmaceuticals position peaked at $45K in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2021.

Based on CVA Family Office's 13F filing for Q4 2021, filed 25 Jan 2022.